CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性大 B 细胞淋巴瘤 CAR-T 细胞治疗前桥接治疗的长期随访
英文原题：Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.
查看英文原题
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
BT 似乎在缓解率、疾病控制、生存和毒性方面均未对结局造成不利影响。
中文摘要
背景
大B细胞淋巴瘤（LBCL）患者在CAR-T 治疗前越来越多接受全身治疗、放疗或联合桥接治疗（BT）。本研究报告商业化CAR-T 治疗患者有无BT的长期结局。
方法
纳入接受商业化CD19 CAR-T 输注的LBCL患者，将放疗分为全面照射和局灶照射，分析疗效与毒性。
结果
156例患者中52.5%接受BT。BT组中位无进展生存期（PFS）为0.65年，未接受BT组为1.45年；中位总生存期分别为3.16年和未达到。全面放疗较局灶放疗显著改善PFS和OS，1年PFS为100%比9.1%，1年OS为100%比45.5%。各队列严重毒性无差异。
结论
BT似乎未损害应答、疾病控制、生存或毒性结局；疾病负荷有限且接受放疗者结局良好。
展开英文摘要原文
BACKGROUND
Bridging therapy (BT) with systemic therapy (ST), radiation therapy (RT), or combined-modality therapy (CMT) is increasingly being utilized prior to chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL). We report the long-term outcomes of the patients who received commercial CAR T-cell therapy with or without BT.
METHODS
The patients with LBCL who underwent infusion of a commercial CD19 CAR T product were eligible. The radiation was stratified as comprehensive or focal. The efficacy outcomes and toxicity were analyzed.
RESULTS
In total, 156 patients were included and, of them, 52.5% of the patients received BT. The median progression-free survival (PFS) was 0.65 years in the BT cohort compared to 1.45 years in the non-BT cohort. The median overall survival (OS) was 3.16 years in the BT cohort and was not reached in the non-BT cohort. The patients who received comprehensive radiation (versus focal) had significantly improved PFS and OS, achieving a 1-year PFS of 100% vs. 9.1% and 1-year OS of 100% vs. 45.5%. There was no difference in the severe toxicity between any of the nonbridging or BT cohorts.
CONCLUSIONS
BT did not appear to compromise outcomes with respect to response rates, disease control, survival, and toxicity. The patients with limited disease treated with RT had favorable outcomes.
论文信息
- 作者
- Ladbury C、Dandapani S、Hao C、Fabros M、Amini A、Sampath S、Glaser S、Sokolov K
- 第一作者单位
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.United States
- 通讯作者单位
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA.United States
- 期刊
- Cancers2023 Mar 14
- 原文标识
- PubMed 36980632 · DOI 10.3390/cancers15061747
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →